JCO Global Oncology最新文献

{"title":"<i>JCO Global Oncology</i> Special Series on International Quality by IQSG.","authors":"Verna Vanderpuye","doi":"10.1200/GO-25-00033","DOIUrl":"https://doi.org/10.1200/GO-25-00033","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500033"},"PeriodicalIF":3.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial Disparities in Endometrial Cancer Incidence and Outcomes in Brazil: Insights From Population-Based Registries.","authors":"Andréia Cristina de Melo, Jessé Lopes da Silva, Eduardo Paulino, Álvaro Ingles Russo Garces, Sofia Vidaurre Mendes, Flora de Moraes Lino da Silva, Bruna Bianca Lopes David, Alexssandra Lima Siqueira Dos Santos, Luiz Claudio Santos Thuler","doi":"10.1200/GO-24-00604","DOIUrl":"https://doi.org/10.1200/GO-24-00604","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to examine trends in the incidence and mortality rates of endometrial cancer (EC) across ethnic groups in Brazil and to analyze the demographic and clinicopathological characteristics associated with these trends.</p><p><strong>Methods: </strong>The incidence of EC was analyzed from 2010 to 2015 using data from Brazilian Population-Based Cancer Registries (PBCRs), including crude rates and annual percentage changes (APCs). Clinical and sociodemographic information from 2000 to 2019 was gathered from Hospital-Based Cancer Registries. Mortality data between 2000 and 2021 were obtained from the National Mortality Information System, allowing for comparisons between White women and Black women.</p><p><strong>Results: </strong>From 2010 to 2015, a total of 32,831 new cases of EC were reported across 13 PBCRs, with Black patients accounting for 35.7% of these cases. The median age at diagnosis was 63 years, with Black women diagnosed at a younger age than White women. Black patients experienced a significant increase in incidence rate (APC +6.7% <i>v</i> +3.0%). A greater proportion of Black patients lived without partners (54.0%), had higher rates of alcohol consumption (15%) and smoking (25.8%), and resided in less developed regions (54.6%) with lower education levels (77.5%). From 2000 to 2021, Brazil recorded 72,189 EC-related deaths, showing higher mortality rates among White women (3.8 per 100,000) than Black women (2.4 per 100,000), although the downward trend was steeper among White women (-1.2%) than Black women (-0.6%).</p><p><strong>Conclusion: </strong>Racial disparities in EC incidence and mortality in Brazil may be closely linked to unfavorable sociodemographic factors faced by Black women. Targeted public health initiatives are critical for improving early detection and access to equitable care for Black women.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400604"},"PeriodicalIF":3.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Analysis Evaluating Treatment Eligibility and Outcomes in Patients With AML Receiving Intensive Chemotherapy: Insights From an Underrepresented Population.","authors":"Hasmukh Jain, Thomas Eipe, Alok Shetty, Lingaraj Nayak, Bhausaheb Pandurang Bagal, Neha Sharma, Akash Pawar, Manju Sengar","doi":"10.1200/GO-24-00482","DOIUrl":"https://doi.org/10.1200/GO-24-00482","url":null,"abstract":"<p><strong>Purpose: </strong>Over the past decade, there have been significant advancements in the treatment of AML. However, similar progress has not been observed in India, with induction mortality rates surpassing those in high-income countries. Our patient population also differs significantly from those in clinical trials, with about 50% ineligible for intensive chemotherapy. Yet, because of limited access to newer therapies and high costs, most of these patients receive intensive therapy.</p><p><strong>Patients and methods: </strong>In this study, we retrospectively classified patients who received intensive induction into fit and unfit groups on the basis of landmark trial criteria. Data were extracted from the Indian Acute Leukemia Research Database, a prospective registry maintained under the Hematology Cancer Consortium. The primary objective was induction mortality.</p><p><strong>Results: </strong>We analyzed 385 patients with AML treated between 2017 and 2019. The median age at diagnosis was 33 years (range, 15-61). Induction mortality was reported at 6.1% in the fit cohort and 20.2% in the unfit cohort (odds ratio, 3.91 [1.97-7.74]; <i>P</i> < .0001). Factors such as increased age, poor performance status, baseline infection, and low albumin were associated with a poor prognosis for early death. After a median follow-up of 19.2 months, the 2-year overall survival in the overall, fit, and unfit cohorts was 62.7%, 67%, and 58.1%, respectively.</p><p><strong>Conclusion: </strong>Our findings highlight the baseline characteristics of our patient population and their impact on the outcomes of induction therapy. Unfit patients who received intensive chemotherapy had higher induction mortality and lower overall survival.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400482"},"PeriodicalIF":3.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143575764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Modeling for Bone Sarcomas Based on a Large Prospective Cohort From a Tertiary Care Cancer Center in India.","authors":"Jyoti Bajpai, Laboni Sarkar, Sushmita Rath, Akash Pawar, Arun Chandrashekharan, Goutam Panda, Dharmpal Jakar, Jaya Ghosh, Siddhartha Laskar, Bharat Rekhi, Nehal Khanna, Jifmi Jose, Mukta Ramdawar, Nilendu Purandare, Prabhat Bhargava, Nivedita Chakrabarty, Kunal Gala, Yogesh Kembhavi, Venkatesh Rangarajan, Shripad Banavali, Sudeep Gupta","doi":"10.1200/GO.24.00142","DOIUrl":"10.1200/GO.24.00142","url":null,"abstract":"<p><strong>Purpose: </strong>Outcomes of adolescents and young adults (AYA) with bone sarcomas including osteosarcoma (OGS) and Ewing sarcoma (ES) are affected by various factors including inadvertent previous treatment and poor compliance. We aimed to develop a risk-scoring system derived and validated at a tertiary care cancer center in India.</p><p><strong>Methods: </strong>All AYA OGS and ES cases treated at our institute with OGS-12 and Ewing's family of tumors-2001 (EFT-2001) protocols from 2011 to 2021 and 2013 to 2018, respectively, were prospectively analyzed. Weighted scores provided to each prognostic variable on the basis of approximate ratios of the beta coefficients of each factor in the multivariable model were summated to divide patients into three clinically discriminatory risk groups, validated by applying separately to derivation, validation, and whole cohorts.</p><p><strong>Results: </strong>Among 606 (81.0%) of 748 AYA with nonmetastatic OGS, significant factors included in the prognostic model were failure to complete protocol (hazard ratio [HR], 2.65), previous treatment (HR, 2.93), necrosis <90% (HR, 1.63), joint involvement (HR, 2.0), and serum alkaline phosphatase >median (204 U/L; HR, 1.63). Of 104 (39.5%) of 263 AYA with ES, significant factors were failure to complete protocol (HR, 2.84), previous treatment (HR, 6.37), necrosis <100% (HR, 8.73), and tumor size >8 cm (HR, 2.64). For 142 (38.8%) of 366 AYA with metastatic OGS, significant factors were failure to complete protocol (HR, 5.29), metastases not amenable to local treatment (HR, 1.96), necrosis <90% (HR, 1.96), and >10 metastases (HR, 2.44). For 38 (43.6%) of 82 AYA with metastatic extremity ES, significant factors were failure to complete protocol (HR, 3.88) and metastases not amenable to local treatment (HR, 10.6).</p><p><strong>Conclusion: </strong>We developed simple, effective prognostic models for AYA with bone sarcomas with specific potential relevance for low- and middle-income countries.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400142"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender and Geographic Characteristics Among Thoracic, GI, and Breast Oncology Editorial Boards: Disparities and Measures to Address Gaps.","authors":"Robert Hsu, Zhaohui Liao Arter, David J Benjamin","doi":"10.1200/GO-24-00656","DOIUrl":"https://doi.org/10.1200/GO-24-00656","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400656"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing the Oncologist Shortage in Latin America: Insights From a Survey of Medical Oncology Fellowship Programs.","authors":"Mauricio Zegarra-López, Alejandro Aranda-Gutierrez, Jose Felipe Muñoz Lozano, Cynthia Villarreal-Garza","doi":"10.1200/GO-24-00462","DOIUrl":"10.1200/GO-24-00462","url":null,"abstract":"<p><strong>Purpose: </strong>Limited information exists about medical oncology fellowship programs in Latin America. Our study aimed to clarify unknowns, with the goal of identifying areas for improvement and potential expansion of fellowships.</p><p><strong>Materials and methods: </strong>Sixteen medical oncologists, each from a different Latin American country, were surveyed using an online questionnaire. Descriptive statistics were used to summarize the collected variables.</p><p><strong>Results: </strong>In total, 232 fellowship programs exist in the surveyed nations, of which 444 medical oncologists graduate every year. Only Argentina, Brazil, Chile, Mexico, and Peru have more than five active fellowship programs. Honduras and Nicaragua did not report any fellowship programs. These nations-along with Colombia, Ecuador, El Salvador, Guatemala, and Peru-depend on foreign education for the training of their medical oncologists. Only one of every 50 medical graduates pursues a career path in medical oncology, and a mere 2.2% of internal medicine residents transition into the field. Nearly half of the data were collected through word of mouth, as many countries lack official, publicly accessible sources for some of the variables studied.</p><p><strong>Conclusion: </strong>This study serves as a pioneering effort that future research groups can build upon. We believe that addressing the shortage of medical oncologists in Latin America by increasing the number of locally trained fellows is the most effective way to swiftly and sustainably improve cancer outcomes.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400462"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Funding Source on Long-Term Outcomes in Prostate Cancer: Analysis of a Large Public Database From Sao Paulo, Brazil.","authors":"Fernando C Maluf, Cintia S K S de Oliveira, Patrícia K Ziegelmann","doi":"10.1200/GO-24-00271","DOIUrl":"10.1200/GO-24-00271","url":null,"abstract":"<p><strong>Purpose: </strong>We investigated the impact of the funding source (public <i>v</i> private) on the overall survival (OS) of men with prostate cancer in Brazil.</p><p><strong>Methods: </strong>We retrospectively analyzed patients with prostate cancer from a large hospital registry from the state of São Paulo, Brazil. Patients age 50-99 years diagnosed with prostate acinar adenocarcinoma or adenocarcinoma not otherwise specified (NOS) between January 2014 and December 2017 were eligible. Demographic and clinical features were analyzed alongside the funding source. On the basis of clinical characteristics at diagnosis (lymph node status, distant metastasis, prostate-specific antigen [PSA], and Gleason score), patients were categorized into low-risk, intermediate-risk, high-risk, and metastatic groups.</p><p><strong>Results: </strong>Of 25,009 patients analyzed, 85% had a public funding source. These patients were slightly older, had greater proportion of adenocarcinoma NOS, and higher PSA levels and risk category. There was a significant difference in OS favoring patients with a private funding source (<i>P</i> < .0001). The estimated OS rates at 5 years were 76.2% (95% CI, 75.6 to 76.9) and 86.9% (95% CI, 85 to 88.7) for the public and private groups, respectively (<i>P</i> < .0001). The funding source was significantly associated with OS independent of age, educational level, and receipt of any treatment in the intermediate-risk (hazard ratio [HR], 2.28 [95% CI, 1.58 to 3.30]; <i>P</i> < .001) and high-risk (HR, 1.36 [95% CI, 1.02 to 1.80]; <i>P</i> = .04) groups, but not in the low-risk (HR, 0.85 [95% CI, 0.60 to 1.21]; <i>P</i> = .38) or metastatic groups (HR, 0.84 [95% CI, 0.64 to 1.11]; <i>P</i> = .23).</p><p><strong>Conclusion: </strong>The worse OS observed for patients with prostate cancer with a public source of funding underscores the need for actions directed to improve the standards of public health care in Brazil.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400271"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-Perceived Barriers to Pediatric Cancer Care in Sub-Saharan Africa: A Cross-Sectional Multinational Study.","authors":"Ole Stoeter, Nikolaus C S Mezger, Tamara Koenig, Eric Chokunonga, Girum Tessema, Adugna Fekadu Damise, Alda Stevy Makouanzi, Esther Majaliwa, Mahine Ivanga, Bakarou Kamate, Franck Gnahatin, Sarah Nambooze, Ima-Obong A Ekanem, Toralf Bernig, Biying Liu, Sumit Gupta, Eva Johanna Kantelhardt","doi":"10.1200/GO.24.00137","DOIUrl":"10.1200/GO.24.00137","url":null,"abstract":"<p><strong>Purpose: </strong>The number of patients with childhood cancer (CC) in sub-Saharan Africa is expected to rise over the coming years. According to the WHO Initiative for Childhood Cancer, access to care is crucial and must be guided by the needs of patients and their families. Our study explored barriers to CC treatment from a patient's perspective to guide the health care providers.</p><p><strong>Methods: </strong>From February to September 2021, we conducted a multinational cross-sectional study with a sample from nine population-based cancer registries in nine sub-Saharan countries. Inclusion criteria comprised a cancer diagnosis according to the International Classification of Childhood Cancer, age 0-19 years, and year of diagnosis 2017-2019. A questionnaire was administered asking families about self-perceived barriers accessing surgery, radiotherapy, and chemotherapy. To assess associated factors, we conducted a multivariable regression analysis presenting the results as odds ratios (ORs).</p><p><strong>Results: </strong>A total of 224 patients with CC was included. The fear of treatment effects and the perceived (poor) health of the child were named most frequently as barriers for all treatment modalities (78.9% and 75.5%, respectively). For chemotherapy, respondents who indicated themselves as rich had lower odds of perceiving the (poor) health of the child as a barrier (OR, 0.06 [95% CI, 0.01 to 0.36]). For radiotherapy, long waiting time and (limited) availability in the country were more commonly barriers (OR, 7.53 [95% CI, 3.38 to 16.78]; OR, 11.11 [95% CI, 2.04 to 60.46], respectively) than for chemotherapy.</p><p><strong>Conclusion: </strong>Despite known barriers such as the availability of therapy, our study additionally indicates the importance of the patients' and families' perceptions of the disease and its treatment. Further expanding measures of social support for affected families should be regarded as one of the main pillars to assure access to care.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400137"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Recruitment and Retention in Cancer Clinical Trials in Low-Resource Settings: Barriers and Facilitators From Nigerian Provider's Perspectives.","authors":"Babayemi O Olakunde, Ngozi Idemili-Aronu, Tara M Friebel-Klingner, Adaeze Chike-Okoli, Ijeoma U Itanyi, Tonia C Onyeka, Kimberly Levinson, Anne F Rositch, Richard B S Roden, Tzyy-Choou Wu, Echezona E Ezeanolue","doi":"10.1200/GO-24-00308","DOIUrl":"10.1200/GO-24-00308","url":null,"abstract":"<p><strong>Purpose: </strong>The under-representation of African countries in cancer clinical trials continues to widen the cancer health disparity. In this study, we assessed health care workers' perspectives on recruitment and retention in cancer clinical trials in Nigeria.</p><p><strong>Methods: </strong>This study was a convergent parallel mixed-methods design, using a survey for quantitative analysis and focus group discussions (FGDs) for further qualitative investigation. The health care providers that participated in the study were drawn from the ICON-3 Practice-based Research Network across the six geopolitical zones in Nigeria.</p><p><strong>Results: </strong>Of the 42 providers, 35 completed the survey and 25 participated in the FGDs. The most cited (agreed or strongly agreed) patient-related barriers were lack of understanding of cancer clinical trials (83%), cultural barriers (77%), and lack of financial compensation for study visits (77%). The most cited provider-related barriers were negative attitude of the clinical team (89%), lack of training in good clinical practice (89%), and an overwhelming clinical workload (86%). On trial-related barriers, about 71% agreed or strongly agreed that lack of trial publicity was a barrier. Over 90% of the respondents agreed or strongly agreed that several factors, including the friendliness of the study team (97%) and clarity in the presentation of trial information (97%), are important facilitators. The FGDs unveiled additional themes, including systems-related barriers such as lack of infrastructure, limited research collaboration, and prolonged ethical approval process, and capacity building and community engagement as potential facilitators.</p><p><strong>Conclusion: </strong>Our study provides providers' perspectives on the barriers and facilitators to the recruitment and retention of participants in cancer clinical trials in a low-resource setting and highlights the need for culturally appropriate recruitment strategies.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400308"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Development and Implementation of a Geriatric Oncology Interdisciplinary Case-Based Educational Intervention for Cancer Care Providers.","authors":"Haydee C Verduzco-Aguirre, Carolina Gomez-Moreno, Ana P Navarrete-Reyes, Gretell Henriquez-Santos, Javier Monroy Chargoy, Abigail Mateos-Soria, Juan José Sánchez Hernández, Alicia Castelo-Loureiro, Liz Hamui-Sutton, Melchor Sánchez-Mendiola, Enrique Soto-Perez-de-Celis","doi":"10.1200/GO-25-00029","DOIUrl":"10.1200/GO-25-00029","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500029"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}